Group
Somatostatin analog
Group Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Other Targeted Agents |
| Mechanism of Action | Somatostatin analog |
| Drugs in group | Lanreotide |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Not radioprotective and at most weak/context-specific radiosensitization; principal RT-relevant role is SSTR2 upregulation for PRRT (Ning et al., Endocrine-Related Cancer, 2009; Adant et al., European Journal of Nuclear Medicine and Molecular Imaging, 2020). With negligible external-beam sensitization, no meaningful theoretical increase in in-field radiation adverse events is expected.
The data above refer to patients treated with Somatostatin analog as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.